Type | Public |
---|---|
Nasdaq: HLTH Russell 3000 Index component | |
Founded | 2010 |
Founders | Ayub Khattak, Clint Sever |
Headquarters | San Diego, California, United States |
Key people | Ayub Khattak (CEO) Clint Sever (Chief Product Officer) |
Revenue | US$618.107 Million (Fiscal Year Ended December 31, 2021)[1] |
US$190.219 Million (Fiscal Year Ended December 31, 2021)[1] | |
US$86.418 Million (Fiscal Year Ended December 31, 2021)[1] | |
Total assets | US$940.060 Million (Fiscal Year Ended December 31, 2021)[1] |
Total equity | US$706.750 Million (Fiscal Year Ended December 31, 2021)[1] |
Number of employees | 500 (January 2021)[2] |
Website | cuehealth.com |
Cue Health is a publicly-traded San Diego, California-based healthcare technology company that develops portable diagnostic tests for at-home use. The company developed the first FDA-authorized COVID-19 diagnostic test for at-home and over-the-counter use without a prescription and physician supervision.
Cue Health was founded as Cue, Inc. in San Diego in 2010, by Ayub Khattak and Clint Sever.[2][3] Khattak became the company's CEO, and Sever became Chief Product Officer.[3]
In November 2014, the company raised $7.5 million in a series A round led by SherpaVentures and Immortalana.[4] Early investors included actor Leonardo DiCaprio, Salesforce CEO Marc Benioff, and political strategist Jim Messina.[5]
In June 2018, the US health agency Biomedical Advanced Research and Development Authority (BARDA), part of the United States Department of Health and Human Services (HHS) awarded $14 million to the company, now named Cue Health, to develop an inexpensive rapid molecular influenza test.[6] In July, the company closed a $45 million Series B round.[7]
In June 2020, the FDA granted Emergency Use Authorization (EUA) to Cue Health for its point-of-care COVID-19 test.[8] Also in June, the company closed a $100 million Series C funding round, with participation from Decheng Capital, Foresite Capital, Madrone Capital Partners, Johnson & Johnson Innovation, ACME Capital and others.[9] In October, the Department of Defense awarded Cue Health a $481 million contract to scale-up its manufacturing and distribute 6 million COVID-19 molecular tests across 10 U.S. states, including Alaska, Florida and Texas.[10][11] The program assisted fishing industry workers in Unalaska, Alaska, who could not easily socially distance, nor access laboratory testing services.[12] In November, the National Basketball Association (NBA) announced it had used Cue's COVID-19 test to safely operate its bubble in Orlando during the 2019-20 NBA season.[13]
In March 2021, the FDA granted Cue Health an EUA for its at-home, non-prescription, over-the-counter molecular COVID-19 test.[14] In April, the company announced its Cue for Schools program to provide K-12 schools and universities with its COVID-19 test.[15] In September, the company went public under the symbol "HLTH" on the NASDAQ at a valuation of about $2.3 billion.[16] In October, the company announced it would be serving as the NBA's official home and point of care COVID-19 testing provider for the 2021–22 season, marking its third straight year of partnership with the league.[17] In November, the company began selling its test directly to consumers.[5] In December, American news magazine Newsweek named Cue Health's home Covid test as one of its favorite products of the month.[18]
In January 2022, Google's parent Alphabet announced they were offering Cue's home tests to employees.[19] It was also reported that Google's cloud division had partnered with Cue Health to develop real-time COVID-19 variant tracking and sequencing, giving Google access to testing and variant data.[20] Also in January, Fast Company reported that the Cue Health reader was one of Google's most popular employee perks.[5]
Cue Health develops molecular testing devices. The company's COVID-19 tests amplify and detect the genomic RNA of SARS-CoV-2, the virus that causes COVID-19. The testing system consists of a swab and cartridge that reads the user's specimen, and an application that produces the results.[21][22][15]
The app also provides access to a mobile health dashboard to connect with on-demand telemedicine, proctoring, and prescription services.[6]
The company also develops a software platform for health providers to manage patient test results and follow-up care.[6]
As of 2018, the company was also reportedly developing a professional-use multiplex test to detect different respiratory pathogens.[6]
Cue Health's headquarters and manufacturing facilities are based in San Diego.[2] As of September 2021, the company reported over 1,250 employees.[23]